Celldex Therapeutics, Inc. Impairment of Intangible Assets, Finite-lived
Celldex Therapeutics, Inc. (CLDX) reported Impairment of Intangible Assets, Finite-lived of $3.50 million for the 3-month period ending 2021-09-30, per its 10-K filed 2022-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2022-02-28
- Celldex Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2021-09-30 was $3.50M.
- Celldex Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2020-06-30 was $3.50M.
- Celldex Therapeutics, Inc. impairment of intangible assets, finite-lived for the quarter ending 2018-03-31 was -$6.90M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month |
|---|---|
| 2021-09-30 | $3.50M 10-K · filed 2022-02-28 |
| 2020-06-30 | $3.50M 10-K · filed 2022-02-28 |
| 2018-03-31 | -$6.90M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |